[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].
Identifieur interne : 000019 ( PubMed/Checkpoint ); précédent : 000018; suivant : 000020[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].
Auteurs :Source :
- Archivos argentinos de pediatria [ 1668-3501 ] ; 2019.
Abstract
Childhood interstitial lung diseases, which some authors refer to as diffuse diseases of the lung, constitute a group of entities that are characterized by remodeling of the interstitium and distal airspaces that cause disturbances of gas exchange in the lungs. While some entities have few symptoms and naturally evolve favorably, others are potentially lethal. Its etiology is very varied, including forms of genetic cause, infectious origin, associated with systemic diseases, drugs and some remain of unknown origin. At present, the development of genetic testing allows diagnosing a group of pathologies, avoiding sometimes a lung biopsy. Its treatment includes different immunosuppressive and immunomodulatory drugs, mainly corticosteroids and hydroxychloroquine, which aim to reduce inflammation, stabilize the disease and prevent the phenomena of remodeling and fibrosis. This consensus is focused on children under 2 years of age, because most of the new entities recently described are manifested at this age.
DOI: 10.5546/aap.2019.S120
PubMed: 31833343
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31833343Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31833343</idno><idno type="pmid">31833343</idno><idno type="doi">10.5546/aap.2019.S120</idno><idno type="wicri:Area/PubMed/Corpus">000014</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000014</idno><idno type="wicri:Area/PubMed/Curation">000014</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000014</idno><idno type="wicri:Area/PubMed/Checkpoint">000019</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].</title></analytic><series><title level="j">Archivos argentinos de pediatria</title><idno type="eISSN">1668-3501</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Childhood interstitial lung diseases, which some authors refer to as diffuse diseases of the lung, constitute a group of entities that are characterized by remodeling of the interstitium and distal airspaces that cause disturbances of gas exchange in the lungs. While some entities have few symptoms and naturally evolve favorably, others are potentially lethal. Its etiology is very varied, including forms of genetic cause, infectious origin, associated with systemic diseases, drugs and some remain of unknown origin. At present, the development of genetic testing allows diagnosing a group of pathologies, avoiding sometimes a lung biopsy. Its treatment includes different immunosuppressive and immunomodulatory drugs, mainly corticosteroids and hydroxychloroquine, which aim to reduce inflammation, stabilize the disease and prevent the phenomena of remodeling and fibrosis. This consensus is focused on children under 2 years of age, because most of the new entities recently described are manifested at this age.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31833343</PMID><DateRevised><Year>2020</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1668-3501</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>04</Month></PubDate></JournalIssue><Title>Archivos argentinos de pediatria</Title><ISOAbbreviation>Arch Argent Pediatr</ISOAbbreviation></Journal><ArticleTitle>[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].</ArticleTitle><Pagination><MedlinePgn>S120-S134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5546/aap.2019.S120</ELocationID><Abstract><AbstractText>Childhood interstitial lung diseases, which some authors refer to as diffuse diseases of the lung, constitute a group of entities that are characterized by remodeling of the interstitium and distal airspaces that cause disturbances of gas exchange in the lungs. While some entities have few symptoms and naturally evolve favorably, others are potentially lethal. Its etiology is very varied, including forms of genetic cause, infectious origin, associated with systemic diseases, drugs and some remain of unknown origin. At present, the development of genetic testing allows diagnosing a group of pathologies, avoiding sometimes a lung biopsy. Its treatment includes different immunosuppressive and immunomodulatory drugs, mainly corticosteroids and hydroxychloroquine, which aim to reduce inflammation, stabilize the disease and prevent the phenomena of remodeling and fibrosis. This consensus is focused on children under 2 years of age, because most of the new entities recently described are manifested at this age.</AbstractText><CopyrightInformation>Sociedad Argentina de Pediatría.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>Comité Nacional de Neumonología, Sociedad Argentina de Pediatría</CollectiveName><AffiliationInfo><Affiliation>amaffey@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016431">Guideline</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Enfermedades del intersticio pulmonar en niños menores de 2 años. Clasificación, diagnóstico y tratamiento.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Arch Argent Pediatr</MedlineTA><NlmUniqueID>0372460</NlmUniqueID><ISSNLinking>0325-0075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las enfermedades intersticiales pulmonares en la infancia, a las que algunos autores se refieren como enfermedades difusas del pulmón, constituyen un grupo de entidades que se caracteriza por la remodelación del intersticio y de los espacios aéreos distales. Mientras algunas entidades tienen pocos síntomas y evolucionan naturalmente en forma favorable, otras pueden ser letales. Su etiología es muy variada e incluye formas de causa genética, origen infeccioso, asociadas a enfermedades sistémicas, fármacos y algunas son de causa desconocida. El desarrollo de estudios genéticos permite, actualmente, diagnosticar un grupo de patologías y, en ocasiones, evitar la biopsia pulmonar. Su tratamiento incluye diferentes drogas inmunosupresoras e inmunomoduladores, sobre todo, corticoides e hidroxicloroquina, que tienen el objetivo de reducir la inflamación y prevenir los fenómenos de remodelación y la fibrosis. Este consenso está enfocado en los niños menores de 2 años, debido a que la mayoría de las nuevas entidades descritas recientemente se manifiestan a esta edad.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">diffuse pulmonary diseases</Keyword><Keyword MajorTopicYN="Y">infants</Keyword><Keyword MajorTopicYN="Y">interstitial lung diseases</Keyword><Keyword MajorTopicYN="Y">lung biopsy</Keyword><Keyword MajorTopicYN="Y">surfactant</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31833343</ArticleId><ArticleId IdType="doi">10.5546/aap.2019.S120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deterding RR. Children’s Interstitial and Diffuse Lung Disease. Progress and Future Horizons. Ann Am Thorac Soc. 2015; 12(10):1451-7.</Citation></Reference><Reference><Citation>Hime NJ, Zurynski Y, Fitzgerald D, Selvadurai H, et al. Childhood interstitial lung disease: A systematic review. Pediatr Pulmonol. 2015; 50(12):1383-92.</Citation></Reference><Reference><Citation>Clement A, ERS Task Force. Task Force on Chronic Interstitial Lung Disease in Immunocompetent Children. Eur Respir J. 2004; 24(4):686-97.</Citation></Reference><Reference><Citation>Nogee LM, Dunbar A 3rd, Wert S, Askin F, et al. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest. 2002; 121(3 Suppl):S20-1.</Citation></Reference><Reference><Citation>Deutsch GH, Young LR, Deterding RR, Fan LL, et al. Diffuse lung disease in young children: Application of a novel classification scheme. Am J Respir Crit Care Med. 2007; 176(11):1120-8.</Citation></Reference><Reference><Citation>Griese M, Haug M, Brasch F, Freihorst A, et al. Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany. Orphanet J Rare Dis. 2009; 4:26.</Citation></Reference><Reference><Citation>Kornum JB, Christensen S, Grijota M, Pedersen L, et al. The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm Med. 2008; 8:24.</Citation></Reference><Reference><Citation>Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol. 2002; 34(1):23-9.</Citation></Reference><Reference><Citation>Andersen C, Ramsay JA, Nogee LM, Shah J, et al. Recurrent familial neonatal deaths: hereditary surfactant protein B deficiency. Am J Perinatol. 2000; 17(4):219-24.</Citation></Reference><Reference><Citation>Fan LL, Kozinetz CA, Deterding RR, Brugman SM. Evaluation of a diagnostic approach to pediatric interstitial lung disease. Pediatrics. 1998; 101(1 Pt1):82-5.</Citation></Reference><Reference><Citation>Vassal HB, Malone M, Petros AJ, Winter RM. Familial persistent pulmonary hypertension of the newborn resulting from misalignment of the pulmonary vessels (congenital alveolar capillary dysplasia). J Med Genet. 1998; 35(1):58-60.</Citation></Reference><Reference><Citation>Boggs S, Harris MC, Hoffman DJ, Goel R, et al. Misalignment of pulmonary veins with alveolar capillary dysplasia: affected siblings and variable phenotypic expression. J Pediatr. 1994; 124(1):125-8.</Citation></Reference><Reference><Citation>Young LR, Brody AS, Inge TH, Acton JD, et al. Neuroendocrine cell distribution and frequency distinguish neuroendocrine cell hyperplasia of infancy from other pulmonary disorders. Chest. 2011; 139(5):1060-71.</Citation></Reference><Reference><Citation>Rusconi F, Castagneto M, Gagliardi L, Leo G, et al. Reference values for respiratory rate in the first 3 years of life. Pediatrics. 1994; 94(3):350-5.</Citation></Reference><Reference><Citation>Kurland G, Deterding RR, Hagood JS, Young LR, et al. An Official American Thoracic Society Clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med. 2013; 188(3):376-94.</Citation></Reference><Reference><Citation>Brody AS. Imaging considerations: interstitial lung disease in children. Radiol Clin North Am. 2005; 43(2):391-403.</Citation></Reference><Reference><Citation>Long FR, Castile RG, Brody AS, Hogan MJ, et al. Lungs in infants and young children: improved thin section CT with a noninvasive controlled-ventilation technique-initial experience. Radiology. 1999; 212(2):588-93.</Citation></Reference><Reference><Citation>Long FR, Castile RG. Technique and clinical applications of full-inflation and end-exhalation controlled-ventilation chest CT in infants and young children. Pediatr Radiol. 2001; 31(6):413-22.</Citation></Reference><Reference><Citation>Deterding RR, Laguna T, Emmett R, Sontag M, et al. Cytokine profiles in bronchoalveolar lavage fluid from children with interstitial lung diseases. Proc Am Thorac Soc. 2006; 3:A164.</Citation></Reference><Reference><Citation>Deterding RR, Pye C, Fan LL, Langston C. Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatr Pulmonol. 2005; 40(2):157-65.</Citation></Reference><Reference><Citation>Sodhi KS, Sharma M, Lee EY, Saxena AK, et al. Diagnostic Utility of 3T Lung MRI in Children with Interstitial Lung Disease: A Prospective Pilot Study. Acad Radiol. 2018; 25(3):380-6.</Citation></Reference><Reference><Citation>Kerby GS, Wilcox SL, Heltshe SL, Accurso FJ, et al. Infant pulmonary function in pediatric interstitial lung disease. Proc Am Thorac Soc. 2005; 2:A474.</Citation></Reference><Reference><Citation>Kerby GS, Kopecky C, Wicox SL, Wagner B, et al. Infant pulmonary function testing in children with neuroendocrine cell hyperplasia with and without lung biopsy. Am J Respir Crit Care Med. 2009; 179:A5965.</Citation></Reference><Reference><Citation>Zysman-Colman Z, Lands LC. Whole Body Plethysmography: Practical Considerations. Paediatr Respir Rev. 2016; 19:39-41.</Citation></Reference><Reference><Citation>Robinson PD, Latzin P, Ramsey KA, Stanojevic S, et al. Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2018; 197(5):e1-19.</Citation></Reference><Reference><Citation>Nathan N, Borensztajn K y Clement A. Genetic causes and clinical management of pediatric interstitial lung diseases. Curr Opin Pulm Med. 2018; 24(3): 253-9.</Citation></Reference><Reference><Citation>Nattes E, Lejeune S, Carsin A, Borie R, et al. Heterogeneity of lung disease associated with NK2 homeobox 1 mutations. Respir Med. 2017; 129:16-23.</Citation></Reference><Reference><Citation>Wittmann T, Schindlbeck U, Höppner S, Kinting S, et al. Tools to explore ABCA3 mutations causing interstitial lung disease. Pediatr Pulmonol. 2016; 51(12):1284-94.</Citation></Reference><Reference><Citation>Gutierrez C, Rodriguez A, Palenzuela S, Forteza C, et al. Congenital misalignment of pulmonary veins with alveolar capillary dysplasia causing persistent neonatal pulmonary hypertension: report of two affected siblings. Pediatr Dev Pathol. 2000; 3(3):271-6.</Citation></Reference><Reference><Citation>Wambach JA, Casey AM, Fishman MP, Wegner DJ, et al. Genotype-phenotype correlations for Infants and children with ABCA3 deficiency. Am J Respir Crit Care Med. 2014; 189(12):1538-43.</Citation></Reference><Reference><Citation>Fan LL, Kozinetz CA. Factors Influencing Survival in Children with Chronic Interstitial Lung Disease. Am J Respir Crit Care Med. 1997; 156(3 Pt 1):939-42.</Citation></Reference><Reference><Citation>Langston C, Dishop M. Infant lung biopsy: Clarifying the pathologic spectrum. Pathol Int. 2004; 54(Suppl 1):S419-21.</Citation></Reference><Reference><Citation>Fortmann C, Schwerk N, Wetzke M, Schukfeh N, et al. Diagnostic accuracy and therapeutic relevance of thoracoscopic lung biopsies in children. Pediatr Pulmonol. 2018; 53(7):948-53.</Citation></Reference><Reference><Citation>Deterding RR, Wagener JS. Lung biopsy in immunocompromised children: when, how, and who? J Pediatr. 2000; 137(2):147-9.</Citation></Reference><Reference><Citation>Bush A, Cunningham S, De Blic J, Barbato A, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015; 70(11):1078-84.</Citation></Reference><Reference><Citation>Niemitz M, Schwerk N, Goldbleck L, Griese M. Development and validation of a health-related quality of life questionnaire for pediatric patients with interstitial lung disease. Pediatr Pulmonol. 2018; 53(7):954-63.</Citation></Reference><Reference><Citation>Comité Nacional de Neumonología, SAP. Guías para el manejo de la oxigenoterapia domiciliaria en pediatría. Parte 2: Sistemas de administración, suspensión del O2. Oxigenoterapia en situaciones especiales. Arch Argent Pediatr. 2013; 111(6):549-55.</Citation></Reference><Reference><Citation>Dinwiddie R. Treatment of interstitial lung disease in children. Paediatr Resp Rev. 2004; 5(2):108-15.</Citation></Reference><Reference><Citation>Desmarquest P, Tamalet A, Fauroux B, Boule M, et al. Chronic interstitial lung disease in children: Response to high‐dose intravenous methylprednisolone pulses. Pediatr Pulmonol. 1998; 26(5):332-8.</Citation></Reference><Reference><Citation>Breuer O, Schultz A. Side effects of medications used to treat childhood interstitial lung disease. Paediatr Respir Rev. 2018: S1526-0542(18)30046-0.</Citation></Reference><Reference><Citation>Avital A, Godfrey S, Maayan CH, Diamant Y, et al. Chloroquine treatment of interstitial lung disease in children. Pediatr Pulmonol. 1994; 18(6): 356-60.</Citation></Reference><Reference><Citation>Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol. 2015; 50(4):410-9.</Citation></Reference><Reference><Citation>Thouvenin G, Nathan N, Epaud R y Clement A. Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin. BMJ Case Rep. 2013;2013: bcr2013009988.</Citation></Reference><Reference><Citation>De Blic J. Pulmonary alveolar proteinosis in children. Paediatr Respir Rev. 2004; 5(4):316-22.</Citation></Reference><Reference><Citation>Liptzin L, Hawkins S, Wagner B, Deterding R. Sleeping child: Neuroendocrine cell hyperplasia of infancy and polysomnography. Pediatr Pulmonol. 2018; 53(7):917-20.</Citation></Reference><Reference><Citation>Woo MS. An overview of paediatric lung transplantation. Paediatr Respir Rev. 2004; 5(3):249-54.</Citation></Reference><Reference><Citation>Mallory GB, Spray TL. Paediatric lung transplantation. Eur Respir J. 2004; 24(5):839-45.</Citation></Reference><Reference><Citation>The International Society for Heart and Lung Transplantation. Registries overview. [Consulta: 6 de noviembre de 2018]. Disponible en: https://www.ishlt.org/registries/overview.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31833343
|texte= [Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31833343" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |